-
1
-
-
34249668818
-
Epidemiology and natural history of NAFLD and NASH
-
[PMID: 17544968]
-
Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007; 11: 1-16, vii [PMID: 17544968 DOI: 10.1016/j.cld.2007.02.009].
-
(2007)
Clin Liver Dis
, vol.11
, pp. 1-16+vii
-
-
Ong, J.P.1
Younossi, Z.M.2
-
2
-
-
84902546574
-
World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
-
[PMID: 24921212]
-
LaBrecque DR, Abbas Z, Anania F, Ferenci P, Khan AG, Goh KL, Hamid SS, Isakov V, Lizarzabal M, Peñaranda MM, Ramos JF, Sarin S, Stimac D, Thomson AB, Umar M, Krabshuis J, LeMair A. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol 2014; 48: 467-473 [PMID: 24921212 DOI: 10.1097/MCG.0000000000000116].
-
(2014)
J Clin Gastroenterol
, vol.48
, pp. 467-473
-
-
LaBrecque, D.R.1
Abbas, Z.2
Anania, F.3
Ferenci, P.4
Khan, A.G.5
Goh, K.L.6
Hamid, S.S.7
Isakov, V.8
Lizarzabal, M.9
Peñaranda, M.M.10
Ramos, J.F.11
Sarin, S.12
Stimac, D.13
Thomson, A.B.14
Umar, M.15
Krabshuis, J.16
LeMair, A.17
-
3
-
-
77952576769
-
Epidemiology of non-alcoholic fatty liver disease
-
[PMID: 20460905]
-
Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010; 28: 155-161 [PMID: 20460905 DOI: 10.1159/000282080].
-
(2010)
Dig Dis
, vol.28
, pp. 155-161
-
-
Bellentani, S.1
Scaglioni, F.2
Marino, M.3
Bedogni, G.4
-
4
-
-
56649123256
-
The epidemiology of nonalcoholic fatty liver disease: a global perspective
-
[PMID: 18956290]
-
Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008; 28: 339-350 [PMID: 18956290 DOI: 10.1055/s-0028-1091978].
-
(2008)
Semin Liver Dis
, vol.28
, pp. 339-350
-
-
Lazo, M.1
Clark, J.M.2
-
5
-
-
84864110034
-
Management of nonalcoholic steatohepatitis: an evidence-based approach
-
[PMID: 22824485]
-
Mahady SE, George J. Management of nonalcoholic steatohepatitis: an evidence-based approach. Clin Liver Dis 2012; 16: 631-645 [PMID: 22824485 DOI: 10.1016/j.cld.2012.05.003].
-
(2012)
Clin Liver Dis
, vol.16
, pp. 631-645
-
-
Mahady, S.E.1
George, J.2
-
6
-
-
83755196306
-
An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD)
-
[PMID: 23148186]
-
Lomonaco R, Chen J, Cusi K. An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD). Ther Adv Endocrinol Metab 2011; 2: 211-225 [PMID: 23148186 DOI: 10.1177/2042018 811419157].
-
(2011)
Ther Adv Endocrinol Metab
, vol.2
, pp. 211-225
-
-
Lomonaco, R.1
Chen, J.2
Cusi, K.3
-
7
-
-
84860273900
-
Nonalcoholic fatty liver disease
-
[PMID: 22541706]
-
Paredes AH, Torres DM, Harrison SA. Nonalcoholic fatty liver disease. Clin Liver Dis 2012; 16: 397-419 [PMID: 22541706 DOI: 10.1016/j.cld.2012.03.005].
-
(2012)
Clin Liver Dis
, vol.16
, pp. 397-419
-
-
Paredes, A.H.1
Torres, D.M.2
Harrison, S.A.3
-
8
-
-
79952231349
-
Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings
-
[PMID: 21319198]
-
Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810-820 [PMID: 21319198 DOI: 10.1002/hep.24127].
-
(2011)
Hepatology
, vol.53
, pp. 810-820
-
-
Brunt, E.M.1
Kleiner, D.E.2
Wilson, L.A.3
Belt, P.4
Neuschwander-Tetri, B.A.5
-
9
-
-
34247384560
-
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD
-
[PMID: 17393509]
-
Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854 [PMID: 17393509 DOI: 10.1002/hep.21496].
-
(2007)
Hepatology
, vol.45
, pp. 846-854
-
-
Angulo, P.1
Hui, J.M.2
Marchesini, G.3
Bugianesi, E.4
George, J.5
Farrell, G.C.6
Enders, F.7
Saksena, S.8
Burt, A.D.9
Bida, J.P.10
Lindor, K.11
Sanderson, S.O.12
Lenzi, M.13
Adams, L.A.14
Kench, J.15
Therneau, T.M.16
Day, C.P.17
-
10
-
-
66149119340
-
Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population
-
[PMID: 19291789]
-
Gastaldelli A, Kozakova M, Højlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Balkau B. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009; 49: 1537-1544 [PMID: 19291789 DOI: 10.1002/hep.22845].
-
(2009)
Hepatology
, vol.49
, pp. 1537-1544
-
-
Gastaldelli, A.1
Kozakova, M.2
Højlund, K.3
Flyvbjerg, A.4
Favuzzi, A.5
Mitrakou, A.6
Balkau, B.7
-
11
-
-
18244364864
-
NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome
-
[PMID: 11826411]
-
Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-379 [PMID: 11826411 DOI: 10.1053/jhep.2002.30692].
-
(2002)
Hepatology
, vol.35
, pp. 373-379
-
-
Chitturi, S.1
Abeygunasekera, S.2
Farrell, G.C.3
Holmes-Walker, J.4
Hui, J.M.5
Fung, C.6
Karim, R.7
Lin, R.8
Samarasinghe, D.9
Liddle, C.10
Weltman, M.11
George, J.12
-
12
-
-
70349764468
-
Role of insulin resistance and lipotoxicity in nonalcoholic steatohepatitis
-
[PMID: 19818304]
-
Cusi K. Role of insulin resistance and lipotoxicity in nonalcoholic steatohepatitis. Clin Liver Dis 2009; 13: 545-563 [PMID: 19818304 DOI: 10.1016/j.cld.2009.07.009].
-
(2009)
Clin Liver Dis
, vol.13
, pp. 545-563
-
-
Cusi, K.1
-
13
-
-
78049522194
-
Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis
-
[PMID: 21038418]
-
Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-1846 [PMID: 21038418 DOI: 10.1002/hep.24001].
-
(2010)
Hepatology
, vol.52
, pp. 1836-1846
-
-
Tilg, H.1
Moschen, A.R.2
-
14
-
-
35748983834
-
Evidence implicating eating as a primary driver for the obesity epidemic
-
[PMID: 17878287]
-
Jeffery RW, Harnack LJ. Evidence implicating eating as a primary driver for the obesity epidemic. Diabetes 2007; 56: 2673-2676 [PMID: 17878287 DOI: 10.2337/db07-1029].
-
(2007)
Diabetes
, vol.56
, pp. 2673-2676
-
-
Jeffery, R.W.1
Harnack, L.J.2
-
15
-
-
84887023370
-
High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase
-
[PMID: 23813872]
-
Ishimoto T, Lanaspa MA, Rivard CJ, Roncal-Jimenez CA, Orlicky DJ, Cicerchi C, McMahan RH, Abdelmalek MF, Rosen HR, Jackman MR, MacLean PS, Diggle CP, Asipu A, Inaba S, Kosugi T, Sato W, Maruyama S, Sánchez-Lozada LG, Sautin YY, Hill JO, Bonthron DT, Johnson RJ. High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology 2013; 58: 1632-1643 [PMID: 23813872 DOI: 10.1002/hep.26594].
-
(2013)
Hepatology
, vol.58
, pp. 1632-1643
-
-
Ishimoto, T.1
Lanaspa, M.A.2
Rivard, C.J.3
Roncal-Jimenez, C.A.4
Orlicky, D.J.5
Cicerchi, C.6
McMahan, R.H.7
Abdelmalek, M.F.8
Rosen, H.R.9
Jackman, M.R.10
MacLean, P.S.11
Diggle, C.P.12
Asipu, A.13
Inaba, S.14
Kosugi, T.15
Sato, W.16
Maruyama, S.17
Sánchez-Lozada, L.G.18
Sautin, Y.Y.19
Hill, J.O.20
Bonthron, D.T.21
Johnson, R.J.22
more..
-
16
-
-
79957796961
-
High-carbohydrate, high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats
-
[PMID: 21572266]
-
Panchal SK, Poudyal H, Iyer A, Nazer R, Alam MA, Diwan V, Kauter K, Sernia C, Campbell F, Ward L, Gobe G, Fenning A, Brown L. High-carbohydrate, high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats. J Cardiovasc Pharmacol 2011; 57: 611-624 [PMID: 21572266 DOI: 10.1097/FJC.0b013e31821b1379].
-
(2011)
J Cardiovasc Pharmacol
, vol.57
, pp. 611-624
-
-
Panchal, S.K.1
Poudyal, H.2
Iyer, A.3
Nazer, R.4
Alam, M.A.5
Diwan, V.6
Kauter, K.7
Sernia, C.8
Campbell, F.9
Ward, L.10
Gobe, G.11
Fenning, A.12
Brown, L.13
-
17
-
-
84918539821
-
A model of metabolic syndrome and related diseases with intestinal endotoxemia in rats fed a high fat and high sucrose diet
-
[PMID: 25502558]
-
Zhou X, Han D, Xu R, Li S, Wu H, Qu C, Wang F, Wang X, Zhao Y. A model of metabolic syndrome and related diseases with intestinal endotoxemia in rats fed a high fat and high sucrose diet. PLoS One 2014; 9: e115148 [PMID: 25502558 DOI: 10.1371/journal. pone.0115148].
-
(2014)
PLoS One
, vol.9
-
-
Zhou, X.1
Han, D.2
Xu, R.3
Li, S.4
Wu, H.5
Qu, C.6
Wang, F.7
Wang, X.8
Zhao, Y.9
-
18
-
-
34548419344
-
Thematic review series: Adipocyte Biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease
-
[PMID: 17699733]
-
Gregor MF, Hotamisligil GS. Thematic review series: Adipocyte Biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J Lipid Res 2007; 48: 1905-1914 [PMID: 17699733 DOI: 10.1194/jlr.R700007-JLR200].
-
(2007)
J Lipid Res
, vol.48
, pp. 1905-1914
-
-
Gregor, M.F.1
Hotamisligil, G.S.2
-
19
-
-
77955690182
-
Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites
-
[PMID: 20683968]
-
Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774-788 [PMID: 20683968 DOI: 10.1002/hep.23719].
-
(2010)
Hepatology
, vol.52
, pp. 774-788
-
-
Neuschwander-Tetri, B.A.1
-
20
-
-
40549135297
-
Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice
-
[PMID: 18317565]
-
Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008; 118: 829-838 [PMID: 18317565 DOI: 10.1172/JCI34275].
-
(2008)
J Clin Invest
, vol.118
, pp. 829-838
-
-
Postic, C.1
Girard, J.2
-
21
-
-
3042824524
-
Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway
-
[PMID: 15239102]
-
Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, Burgart LJ, Gores GJ. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004; 40: 185-194 [PMID: 15239102 DOI: 10.1002/hep.20283].
-
(2004)
Hepatology
, vol.40
, pp. 185-194
-
-
Feldstein, A.E.1
Werneburg, N.W.2
Canbay, A.3
Guicciardi, M.E.4
Bronk, S.F.5
Rydzewski, R.6
Burgart, L.J.7
Gores, G.J.8
-
22
-
-
33747626511
-
Mitochondrial free cholesterol loading sensitizes to TNF-and Fas-mediated steatohepatitis
-
[PMID: 16950136]
-
Marí M, Caballero F, Colell A, Morales A, Caballeria J, Fernandez A, Enrich C, Fernandez-Checa JC, García-Ruiz C. Mitochondrial free cholesterol loading sensitizes to TNF-and Fas-mediated steatohepatitis. Cell Metab 2006; 4: 185-198 [PMID: 16950136 DOI: 10.1016/j.cmet.2006.07.006].
-
(2006)
Cell Metab
, vol.4
, pp. 185-198
-
-
Marí, M.1
Caballero, F.2
Colell, A.3
Morales, A.4
Caballeria, J.5
Fernandez, A.6
Enrich, C.7
Fernandez-Checa, J.C.8
García-Ruiz, C.9
-
23
-
-
84861543083
-
The diagnosis and management of nonalcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
-
[PMID: 22488764]
-
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023 [PMID: 22488764 DOI: 10.1002/hep.25762].
-
(2012)
Hepatology
, vol.55
, pp. 2005-2023
-
-
Chalasani, N.1
Younossi, Z.2
Lavine, J.E.3
Diehl, A.M.4
Brunt, E.M.5
Cusi, K.6
Charlton, M.7
Sanyal, A.J.8
-
24
-
-
33846006173
-
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
-
[PMID: 17098089]
-
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705 [PMID: 17098089 DOI: 10.1016/S0140-6736(06)69705-5].
-
(2006)
Lancet
, vol.368
, pp. 1696-1705
-
-
Drucker, D.J.1
Nauck, M.A.2
-
25
-
-
84936952283
-
Shortterm intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome
-
Epub ahead of print [PMID: 25330463]
-
Jensterle M, Kocjan T, Kravos NA, Pfeifer M, Janez A. Shortterm intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome. Endocr Res 2014; Epub ahead of print [PMID: 25330463 DOI: 10.3109/07435800.20 14.966385].
-
(2014)
Endocr Res
-
-
Jensterle, M.1
Kocjan, T.2
Kravos, N.A.3
Pfeifer, M.4
Janez, A.5
-
26
-
-
84896270054
-
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin
-
[PMID: 24362411]
-
Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol 2014; 170: 451-459 [PMID: 24362411 DOI: 10.1530/EJE-13-0797].
-
(2014)
Eur J Endocrinol
, vol.170
, pp. 451-459
-
-
Jensterle Sever, M.1
Kocjan, T.2
Pfeifer, M.3
Kravos, N.A.4
Janez, A.5
-
27
-
-
84859046364
-
Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes
-
[PMID: 22040840]
-
Dushay J, Gao C, Gopalakrishnan GS, Crawley M, Mitten EK, Wilker E, Mullington J, Maratos-Flier E. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabetes Care 2012; 35: 4-11 [PMID: 22040840 DOI: 10.2337/dc11-0931].
-
(2012)
Diabetes Care
, vol.35
, pp. 4-11
-
-
Dushay, J.1
Gao, C.2
Gopalakrishnan, G.S.3
Crawley, M.4
Mitten, E.K.5
Wilker, E.6
Mullington, J.7
Maratos-Flier, E.8
-
28
-
-
84865251381
-
Alterations in energy balance following exenatide administration
-
[PMID: 22735035]
-
Bradley DP, Kulstad R, Racine N, Shenker Y, Meredith M, Schoeller DA. Alterations in energy balance following exenatide administration. Appl Physiol Nutr Metab 2012; 37: 893-899 [PMID: 22735035 DOI: 10.1139/h2012-068].
-
(2012)
Appl Physiol Nutr Metab
, vol.37
, pp. 893-899
-
-
Bradley, D.P.1
Kulstad, R.2
Racine, N.3
Shenker, Y.4
Meredith, M.5
Schoeller, D.A.6
-
29
-
-
77949273334
-
The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
-
[PMID: 19957161]
-
Hsieh J, Longuet C, Baker CL, Qin B, Federico LM, Drucker DJ, Adeli K. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 2010; 53: 552-561 [PMID: 19957161 DOI: 10.1007/s00125-009-1611-5].
-
(2010)
Diabetologia
, vol.53
, pp. 552-561
-
-
Hsieh, J.1
Longuet, C.2
Baker, C.L.3
Qin, B.4
Federico, L.M.5
Drucker, D.J.6
Adeli, K.7
-
30
-
-
77956230708
-
Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus
-
[PMID: 20557887]
-
Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 2010; 212: 217-222 [PMID: 20557887 DOI: 10.1016/j.atherosclerosis.2010.0 5.028].
-
(2010)
Atherosclerosis
, vol.212
, pp. 217-222
-
-
Schwartz, E.A.1
Koska, J.2
Mullin, M.P.3
Syoufi, I.4
Schwenke, D.C.5
Reaven, P.D.6
-
31
-
-
77951151612
-
Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4
-
[PMID: 20068138]
-
Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010; 59: 1030-1037 [PMID: 20068138 DOI: 10.2337/db09-1694].
-
(2010)
Diabetes
, vol.59
, pp. 1030-1037
-
-
Arakawa, M.1
Mita, T.2
Azuma, K.3
Ebato, C.4
Goto, H.5
Nomiyama, T.6
Fujitani, Y.7
Hirose, T.8
Kawamori, R.9
Watada, H.10
-
32
-
-
33748442464
-
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
-
[PMID: 16776751]
-
Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436-447 [PMID: 16776751 DOI: 10.1111/j.1463-1326.2006.00602.x].
-
(2006)
Diabetes Obes Metab
, vol.8
, pp. 436-447
-
-
Blonde, L.1
Klein, E.J.2
Han, J.3
Zhang, B.4
Mac, S.M.5
Poon, T.H.6
Taylor, K.L.7
Trautmann, M.E.8
Kim, D.D.9
Kendall, D.M.10
-
33
-
-
8544258807
-
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
-
[PMID: 15353407]
-
Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, Sjöholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287: E1209-E1215 [PMID: 15353407 DOI: 10.1152/ajpendo.00237.2004].
-
(2004)
Am J Physiol Endocrinol Metab
, vol.287
, pp. E1209-E1215
-
-
Nyström, T.1
Gutniak, M.K.2
Zhang, Q.3
Zhang, F.4
Holst, J.J.5
Ahrén, B.6
Sjöholm, A.7
-
34
-
-
38549162147
-
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
-
[PMID: 18053320]
-
Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275-286 [PMID: 18053320 DOI: 10.1185/030079908X2 53870].
-
(2008)
Curr Med Res Opin
, vol.24
, pp. 275-286
-
-
Klonoff, D.C.1
Buse, J.B.2
Nielsen, L.L.3
Guan, X.4
Bowlus, C.L.5
Holcombe, J.H.6
Wintle, M.E.7
Maggs, D.G.8
-
35
-
-
82455212124
-
Exenatide decreases hepatic fibroblast growth factor 21 resistance in nonalcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial
-
[PMID: 21956711]
-
Samson SL, Sathyanarayana P, Jogi M, Gonzalez EV, Gutierrez A, Krishnamurthy R, Muthupillai R, Chan L, Bajaj M. Exenatide decreases hepatic fibroblast growth factor 21 resistance in nonalcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia 2011; 54: 3093-3100 [PMID: 21956711 DOI: 10.1007/s00125-011-2317-z].
-
(2011)
Diabetologia
, vol.54
, pp. 3093-3100
-
-
Samson, S.L.1
Sathyanarayana, P.2
Jogi, M.3
Gonzalez, E.V.4
Gutierrez, A.5
Krishnamurthy, R.6
Muthupillai, R.7
Chan, L.8
Bajaj, M.9
-
36
-
-
84898613866
-
A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes
-
[PMID: 24122776]
-
Wilkins JJ, Dubar M, Sébastien B, Laveille C. A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes. J Clin Pharmacol 2014; 54: 267-278 [PMID: 24122776 DOI: 10.1002/jcph.192].
-
(2014)
J Clin Pharmacol
, vol.54
, pp. 267-278
-
-
Wilkins, J.J.1
Dubar, M.2
Sébastien, B.3
Laveille, C.4
-
37
-
-
77951276732
-
Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat
-
[PMID: 20590744]
-
Sebokova E, Bénardeau A, Sprecher U, Sewing S, Tobalina L, Migliorini C. Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat. Diabetes Obes Metab 2010; 12: 674-682 [PMID: 20590744 DOI: 10.1111/j. 1463-1326.2010.0120 7.x].
-
(2010)
Diabetes Obes Metab
, vol.12
, pp. 674-682
-
-
Sebokova, E.1
Bénardeau, A.2
Sprecher, U.3
Sewing, S.4
Tobalina, L.5
Migliorini, C.6
-
38
-
-
79957668323
-
Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success
-
[PMID: 21635988]
-
Aguilar RB. Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success. Clin Ther 2011; 33: 408-424 [PMID: 21635988 DOI: 10.1016/j.clinthera.2011.04.008].
-
(2011)
Clin Ther
, vol.33
, pp. 408-424
-
-
Aguilar, R.B.1
-
39
-
-
84910603708
-
Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation
-
[PMID: 25356042]
-
Wang XC, Gusdon AM, Liu H, Qu S. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. World J Gastroenterol 2014; 20: 14821-14830 [PMID: 25356042 DOI: 10.3748/wjg.v20.i40.14821].
-
(2014)
World J Gastroenterol
, vol.20
, pp. 14821-14830
-
-
Wang, X.C.1
Gusdon, A.M.2
Liu, H.3
Qu, S.4
-
40
-
-
77951436599
-
Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway
-
[PMID: 20225248]
-
Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010; 51: 1584-1592 [PMID: 20225248 DOI: 10.1002/hep.23569].
-
(2010)
Hepatology
, vol.51
, pp. 1584-1592
-
-
Gupta, N.A.1
Mells, J.2
Dunham, R.M.3
Grakoui, A.4
Handy, J.5
Saxena, N.K.6
Anania, F.A.7
-
41
-
-
34248223285
-
Biology of incretins: GLP-1 and GIP
-
[PMID: 17498508]
-
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157 [PMID: 17498508 DOI: 10.1053/j.gastro.2007.03.054].
-
(2007)
Gastroenterology
, vol.132
, pp. 2131-2157
-
-
Baggio, L.L.1
Drucker, D.J.2
-
42
-
-
84907248363
-
DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus
-
[PMID: 25228119]
-
Kanazawa I, Tanaka K, Sugimoto T. DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus. Med Sci Monit 2014; 20: 1662-1667 [PMID: 25228119 DOI: 10.12659/MSM.890989].
-
(2014)
Med Sci Monit
, vol.20
, pp. 1662-1667
-
-
Kanazawa, I.1
Tanaka, K.2
Sugimoto, T.3
-
43
-
-
79954764140
-
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
-
[PMID: 21145828]
-
Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, Sogni P, Maynard M, Larrey D, Serfaty L, Bonnefont-Rousselot D, Bastard JP, Rivière M, Spénard J. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011; 54: 1011-1019 [PMID: 21145828 DOI: 10.1016/j.jhep.2010.08.030].
-
(2011)
J Hepatol
, vol.54
, pp. 1011-1019
-
-
Ratziu, V.1
de Ledinghen, V.2
Oberti, F.3
Mathurin, P.4
Wartelle-Bladou, C.5
Renou, C.6
Sogni, P.7
Maynard, M.8
Larrey, D.9
Serfaty, L.10
Bonnefont-Rousselot, D.11
Bastard, J.P.12
Rivière, M.13
Spénard, J.14
-
44
-
-
84929266699
-
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
-
[PMID: 25468160]
-
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385: 956-965 [PMID: 25468160 DOI: 10.1016/S0140-6736(14)61933-4].
-
(2015)
Lancet
, vol.385
, pp. 956-965
-
-
Neuschwander-Tetri, B.A.1
Loomba, R.2
Sanyal, A.J.3
Lavine, J.E.4
Van Natta, M.L.5
Abdelmalek, M.F.6
Chalasani, N.7
Dasarathy, S.8
Diehl, A.M.9
Hameed, B.10
Kowdley, K.V.11
McCullough, A.12
Terrault, N.13
Clark, J.M.14
Tonascia, J.15
Brunt, E.M.16
Kleiner, D.E.17
Doo, E.18
-
45
-
-
84888023932
-
Obesity and NAFLD: the role of bacteria and microbiota
-
[PMID: 24274865]
-
Duseja A, Chawla YK. Obesity and NAFLD: the role of bacteria and microbiota. Clin Liver Dis 2014; 18: 59-71 [PMID: 24274865 DOI: 10.1016/j.cld.2013.09.002].
-
(2014)
Clin Liver Dis
, vol.18
, pp. 59-71
-
-
Duseja, A.1
Chawla, Y.K.2
-
46
-
-
4844228675
-
Probiotics: a potential target for the prevention and treatment of steatohepatitis
-
[PMID: 15220676]
-
Nardone G, Rocco A. Probiotics: a potential target for the prevention and treatment of steatohepatitis. J Clin Gastroenterol 2004; 38: S121-S122 [PMID: 15220676 DOI: 10.1097/01.mcg.0000128934.53920.1d].
-
(2004)
J Clin Gastroenterol
, vol.38
, pp. S121-S122
-
-
Nardone, G.1
Rocco, A.2
-
47
-
-
79551678401
-
Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice
-
[PMID: 21281408]
-
Naito E, Yoshida Y, Makino K, Kounoshi Y, Kunihiro S, Takahashi R, Matsuzaki T, Miyazaki K, Ishikawa F. Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. J Appl Microbiol 2011; 110: 650-657 [PMID: 21281408 DOI: 10.1111/j. 1365-2672.2010.0 4922.x].
-
(2011)
J Appl Microbiol
, vol.110
, pp. 650-657
-
-
Naito, E.1
Yoshida, Y.2
Makino, K.3
Kounoshi, Y.4
Kunihiro, S.5
Takahashi, R.6
Matsuzaki, T.7
Miyazaki, K.8
Ishikawa, F.9
-
48
-
-
0037309589
-
Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease
-
[PMID: 12540784]
-
Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, Desimone C, Song XY, Diehl AM. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-350 [PMID: 12540784 DOI: 10.1053/jhep.2003.50048].
-
(2003)
Hepatology
, vol.37
, pp. 343-350
-
-
Li, Z.1
Yang, S.2
Lin, H.3
Huang, J.4
Watkins, P.A.5
Moser, A.B.6
Desimone, C.7
Song, X.Y.8
Diehl, A.M.9
-
49
-
-
84875496910
-
Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model
-
[PMID: 22749137]
-
Wagnerberger S, Spruss A, Kanuri G, Stahl C, Schröder M, Vetter W, Bischoff SC, Bergheim I. Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model. J Nutr Biochem 2013; 24: 531-538 [PMID: 22749137 DOI: 10.1016/j.jnutbio.2012.01.014].
-
(2013)
J Nutr Biochem
, vol.24
, pp. 531-538
-
-
Wagnerberger, S.1
Spruss, A.2
Kanuri, G.3
Stahl, C.4
Schröder, M.5
Vetter, W.6
Bischoff, S.C.7
Bergheim, I.8
-
50
-
-
63349101854
-
VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice
-
[PMID: 19115316]
-
Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P, Szabo G. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009; 49: 989-997 [PMID: 19115316 DOI: 10.1002/hep.22711].
-
(2009)
Hepatology
, vol.49
, pp. 989-997
-
-
Velayudham, A.1
Dolganiuc, A.2
Ellis, M.3
Petrasek, J.4
Kodys, K.5
Mandrekar, P.6
Szabo, G.7
-
51
-
-
20844440555
-
Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases
-
[PMID: 15942443]
-
Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, Del Vecchio Blanco C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39: 540-543 [PMID: 15942443 DOI: 10.1097/01.mcg.0000165671.25272.0f].
-
(2005)
J Clin Gastroenterol
, vol.39
, pp. 540-543
-
-
Loguercio, C.1
Federico, A.2
Tuccillo, C.3
Terracciano, F.4
D'Auria, M.V.5
De Simone, C.6
Del Vecchio Blanco, C.7
|